The management of ITP during and after the COVID-19 pandemic

In this video, Drew Provan, BSc, MBChB, MD, FRCP, FRCPath, Queen Mary University of London, London, UK, shares some insights into how the treatment and management of immune thrombocytopenia (ITP) changed during and after the COVID-19 pandemic. Dr Provan highlights how access to certain agents impacted treatment approaches, and further comments on future aspects to consider in the treatment of ITP. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.